Company news

Lumos Diagnostics Holdings Ltd. news in 2026

Lumos Diagnostics Holdings Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Investor Presentation

October 26, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 26, 2026

Application for quotation of securities - LDX

October 19, 2026

Q1 FY27 Quarterly Results Date & Webinar Invitation

October 18, 2026

Final Director's Interest Notice - LM

October 12, 2026

Initial Director's Interest Notice - AS

October 12, 2026

Notice of Annual General Meeting and Proxy Form

October 12, 2026

Lumos Diagnostics Board Changes

October 11, 2026

Notification of cessation of securities - LDX

October 8, 2026

Section 708A Cleansing Statement

September 29, 2026

Application for quotation of securities - LDX

September 29, 2026

Change in substantial holding for LDX

September 15, 2026

Section 708A Cleansing Statement

September 14, 2026

Application for quotation of securities - LDX

September 14, 2026

FebriDx Commercial Traction Continues Across US Accounts

September 14, 2026

Section 708A Cleansing Statement

August 31, 2026

Application for quotation of securities - LDX

August 31, 2026

Change of Director's Interest Notice - DW

August 31, 2026

Appendix 4G and Corporate Governance Statement

August 25, 2026

FY26 Full Year Results Announcement

August 25, 2026

FY26 Appendix 4E

August 25, 2026

FY26 Annual Report

August 25, 2026

Lumos to Present at 20th Bioshares Biotech Summit

August 6, 2026

Lumos Receives FebriDx Order from PHASE Scientific

August 3, 2026

Lumos Secures Distribution for FebriDx in Romania

July 29, 2026

Change of Director's Interest Notice - DW

July 27, 2026

Section 708A Cleansing Statement

July 27, 2026

Application for quotation of securities - LDX

July 27, 2026

FebriDx Commercial Traction Across Priority US Accounts

July 20, 2026

FebriDx U.S. Rollout and Reimbursement Update - Amended

May 18, 2026

FebriDx U.S. Rollout and Reimbursement Update

May 17, 2026

FebriDx Paediatric Study Enrolment Milestone Achieved

May 13, 2026

Response to ASX Aware Letter

April 10, 2026

Prospectus

April 9, 2026

Lumos secures new contract manufacturing agreement

April 8, 2026

Lumos receives largest FebriDx order to date

April 1, 2026

Investor Presentation

March 26, 2026

Lumos completes $20m placement and launches SPP

March 26, 2026

US FDA Grants CLIA Waiver for FebriDx

March 26, 2026

Trading Halt

March 24, 2026

Lumos Delivers Several Pivotal Milestones in 1H FY26

February 26, 2026

Appendix 4D and Half Year Report

February 26, 2026

Lumos Completes Enrolment Milestone for Paediatric Study

February 22, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

Calls in 2026

Decks in 2026